Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Inc. Second Quarter 2025 Earnings Call. Please note this event is being recorded. I would now like to turn the conference over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahead.

Thank you very much. Good morning, and welcome to Novanta's Second Quarter 2025 Earnings Conference Call. This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. If you've not received a copy of our earnings press release issued today, you may obtain it from the Investor Relations section of our website at www.novanta.com. Please note, this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued earlier today and also those in our SEC filings. We may make some comments today, both in our prepared remarks and in our responses to questions that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. So you should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release. To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the Investor Relations section of our website after this call. I'm now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra.

Thank you, Ray. Good morning, everybody, and thanks for joining our call. Novanta delivered solid second quarter results, meeting or exceeding expectations for sales, margins and profit. Revenue reached $241 million, which represents reported revenue growth of 2% and organic revenue declines of 2%, surpassing guidance. New product revenue grew by over 50% year-over-year. Customer orders grew 10% year-over-year and 20% sequentially, reflecting a strengthening outlook. We also saw significant design win activity growing more than 150% year-over-year. Adjusted gross margins held at 46% and adjusted EBITDA margin was 22%, both in line with expectations. These results reflect the strength of Novanta's business model, team and culture and the power of using the Novanta Growth System to optimize company performance in a very fluid macroeconomic and trade environment. And I'm proud of the team's strong execution of our tariff response strategy. Our long-term growth strategy remains focused on winning in markets with long-term secular tailwinds such as precision and AI-driven robotics and automation, advanced minimally invasive and robotic surgery and precision medicine. We built trusted long-term collaborative partnerships with the world's leading OEM customers by solving their most challenging needs with our proprietary technology solutions, securing up to 10 years of exclusive and sticky designing platforms. While our products typically represent no more than 10% of our customers' bill of material, they enable differentiation and innovation in their systems for their customers in terms of clinical outcome, throughput, yield, cost per procedure or part or never-before-possible performance. In the last decade, our portfolio has evolved significantly. We've expanded into health care growth markets, which are now approximately 55% of our business. We have increased our recurring consumables revenue to approximately 15% of sales. And we have increased our revenue from intelligent subsystems with embedded software to approximately 30% of sales, which is margin accretive for Novanta. We intend to continue to expand our portfolio into these areas. Now let me provide an update on the customer demand and market dynamics that we're seeing. Our sales to medical device markets remain exceptionally strong with patient procedure growth rates, hospital spending and our share gains driving sustained double-digit growth in our Advanced Surgery business in the second quarter and year-to-date. Our new product launches in surgical robotics and minimally invasive surgery applications are ramping very successfully. These products are designed to significantly enhance patient safety, improve surgical throughput and help meet new regulatory requirements as U.S. states and countries around the world pass legislation regarding surgical smoke evacuation. Novanta is on track to reach $50 million of incremental new product revenue for 2025, mainly due to the strong outlook for the next-generation medical devices. Rapid adoption of these products supports our confidence that the Advanced Surgery business revenue will nearly double by 2030, up from $200 million in 2024. Medical consumables, a strategic focus for Novanta are expected to account for approximately 15% of sales in 2025 with ongoing double-digit growth rates. Our success stems from long-term innovation investment and strong customer relationships, and we believe we now have the expertise and scale to expand into adjacent recurring medical consumable segments. We're also very excited to announce 2 major design wins in the second quarter in the minimally invasive surgery market. First, we won a new product program with one of the largest medical OEM customers to develop a third-generation insufflator device and consumables which will be launched in the next few years. This design win shows our strong long-term partnership with winning OEMs and our ability to provide leading-edge innovations over multiple generations of our products. Second, with a separate medical OEM customer, we won a contract to develop a next-generation pump for their upcoming endoscopy tower. Our product will provide multifunctional pump capabilities along with proprietary sensing and seamless integration with other devices on the customer's tower. This represents our second major win of next-generation pumps with more in progress. Moving on, our robotics and automation applications continue to see strong demand despite the global trade disruptions as evidenced by the strong double-digit revenue growth in the second quarter. Growth in this business is driven by demand for our products that support physical AI applications such as warehouse automation, precision robotics and humanoids. We expect sales into these applications to double in 2026 versus 2025 and then to double again in 2027. We believe these physical AI applications represent an incremental $1 billion addressable market for Novanta by 2030. To that point, we're excited to announce a significant contract signed in July with a leading e-commerce and warehouse robotics company. This represents a $50 million revenue opportunity over the next 3 years. Because of the timing, this design win will be included in our third quarter metrics and revenue will start in '26. Taking a step back, the warehouse automation space is booming because of AI, labor shortages and latest advancements in physical AI sensor technologies. As a result, leading OEM players are aggressively deploying high conviction use cases. Novanta's proprietary technology offers precise touch and safe movement for robots, enabling smarter, faster and more efficient goods handling, critical capabilities for more modern warehouse operations. I'm also pleased to share progress in humanoid robotics. This emerging field is in early development, and we're collaborating with over 10 leading humanoid players across North America and Europe. We're working with these players on multiple slots with significant content. We hope to announce specific design wins in the future as this market matures and these players finalize their product architectures. The same unique Novanta sensing and servo drive capabilities that are used in warehouse automation and surgical robotics are also relevant in humanoids. So we have a competitive advantage with platform technologies relevant for multiple physical AI robotics applications. This advantage has been built up over years with our growth playbook, consistent investment in innovation, combined with in-depth application know-how, targeted acquisitions and customer intimacy. Turning to other markets. Sales to industrial capital equipment saw declines year-over-year. This market is mainly served by our precision manufacturing business, which was affected by the impact of trade disruptions on customer demand, particularly in China. However, revenue has now stabilized at this lower level and bookings are rising at double-digit pace, both year-over-year and sequentially as customer inventories are mostly depleted and visibility improves. Coupled with the new design wins more than doubling year-over-year for the second consecutive quarter, this positions us well for sequential revenue growth through the second half of 2025 and beyond. We're gaining traction in additive manufacturing for medical and aerospace applications and applications supporting AI investments like advanced packaging and on-device AI computing, which demand extreme precision throughput and miniaturization, areas where Novanta scan head subsystems excel. Also, as supply chains regionalize, we see growth opportunities in new markets such as India, where we are expanding our commercial presence and have had recent success winning new customers. Next, in advanced semiconductor applications. In the near term, this market continues to show mixed signals, but appears to be in the early phases of an up cycle, albeit at a slow pace. Our short-cycle sales are still strong on the back of capacity build-out for new data centers and other AI-related infrastructure. As for our new content in deep UV and EUV applications, we're shipping small amounts of early units, and we will be ramping up as our customer ramps in the marketplace. We're designed in on an exclusive basis with this new content, and we expect significant sales growth over the next few years. Finally, speaking to life science equipment markets, which is mainly served by our Precision Medicine business. This area saw a year-over-year decline caused by weak end market dynamics, including further disruptions at the U.S. NIH and FDA, weak biotech funding, cutbacks in pharma CapEx and trade disruptions. Due to these market disruptions, we're starting to see customers accelerate the replacement cycle away from barcoding and older instruments as they focus their new product development on more advanced technologies such as RFID and machine vision. Over the last 2 years, we've been aggressively shifting our product offering into these new technologies. For RFID, we feel that with the Kion acquisition, we've successfully positioned ourselves at the leading edge of new RFID solutions offerings. And as for machine vision, we're happy to announce that in the second quarter, we entered into a new commercial partnership with a global leader in machine vision technologies to sell their embedded machine vision to OEM customers in the life sciences sectors. This partnership leverages our partners' leading machine vision technology combined with Novanta's deep domain and application knowledge of medical and life science applications, including our ability to provide tailored support to our OEM customers. And so while the recent decline in revenue has been more than expected, we were encouraged to see our Precision Medicine business grow double digits sequentially in the second quarter, largely because of our accelerated transition to these more advanced technologies. Based on this, we believe the revenue will stabilize over the next several quarters and expect it to grow sequentially for the remainder of this year. We continue to believe in the long-term secular opportunities in the life science equipment market. Early detection of the root cause of disease will continue to be a big driver of productivity in the health care industry, and we will continue to execute our long-term growth playbook in this market, albeit that in the near term, we're managing the profit flow-through of this business and shifting our capital allocation plans. Now I'll provide an update on our acquisition activities. The Kion integration is on track, and the business performance is already beating our initial expectations. Our short time with this team has proven their leading expertise in software development and RFID technology solutions. And they also have succeeded at winning a large new customer, which we believe will offer excellent near-term growth for the business, helping the second half sales outlook of 2025 with continued double-digit growth in 2026. Looking beyond Kion, acquisitions remain a top priority for our team to continue to evolve our portfolio towards high-growth medical, more recurring consumable-based and more embedded software and intelligent subsystems. We continue to have a large and exciting pipeline of targets. Valuation levels are more attractive, and we believe that the near-term macroeconomic environment is an added catalyst to increase actionability. Our balance sheet is well positioned for additional transactions while maintaining our historical discipline in both cash returns and financial leverage. You should expect us to lean in hard to pursue additional transactions in the second half of 2025. So to conclude, I'm very pleased with our second quarter performance. We met or exceeded our expectations for sales, margins and profit, driven by double-digit growth in our Advanced Surgery and Robotics Automation businesses, underscoring our strategic focus on high-growth markets and the diversity of our portfolio. Our new product launches continue to ramp, and we remain confident in achieving our goal of $50 million incremental new product sales. We also had 10% year-over-year growth in bookings, which, combined with the new product ramp sets us up for steadily increasing sequential growth in 2025. We're also well positioned for growth in 2026 based on multiple significant new design wins in high-growth end markets such as minimally invasive surgery and also physical AI applications like warehouse robotics. And finally, the Kion acquisition is off to a great start, and we have an additional large pipeline of exciting actionable acquisition targets. We remain focused on our top 3 priorities for Novanta in 2025. First, ramp all our planned new products and achieve the $50 million growth from new products this year. Second, deliver strong profit margin and cash flow performance by driving NGS deep into our culture and operations and successfully execute on our tariff response playbook. And third, acquire additional companies that fit our strategy at attractive returns and in a manner that evolves our portfolio to secular growing and resilient markets and business model. So with that, I will turn the call over to Robert to provide more details on our operations and financial performance.

Thank you, Matthijs. Our second quarter 2025 non-GAAP adjusted gross profit was $111 million or 46.1% adjusted gross margin compared to $110 million or 46.6% adjusted gross margin in the second quarter of 2024. Adjusted gross margins were down year-over-year, but flat sequentially and in line with our expectations despite the increased cost of tariffs. For the second quarter, R&D expenses were $25 million or approximately 10% of sales. Second quarter SG&A expenses, excluding ERP design costs, were $45 million or approximately 19% of sales. The ERP design costs for the quarter were approximately $1 million. Adjusted EBITDA was $52 million in the second quarter or 22% adjusted EBITDA margin, demonstrating growth of 2% year-over-year. On the tax front, our non-GAAP tax rate for the second quarter of 2025 was 21% versus 20% in the prior year. Our tax rate increased year-over-year, mainly due to changes in jurisdictional mix of pretax income. Our non-GAAP adjusted earnings per share was $0.76 in the second quarter, up 4% versus the prior year. Operating cash flow for the second quarter of 2025 was $15 million compared to $41 million in the second quarter of 2024. The year-over-year decrease in operating cash flow was primarily driven by the timing of tax payments, an increase in inventory purchases to mitigate the global trade dynamics, which were at their peak in the second quarter and from the acquisition of Kion. We expect cash flow conversion rates to return closer to historical averages in the third quarter. We ended the second quarter with gross debt of $465 million with a gross leverage ratio of 2.2x, and our net debt was $355 million, giving us a net leverage ratio of approximately 1.7x. In the quarter, we acquired Kion Technologies for approximately $75 million. As a reminder, Kion combines proprietary RFID hardware with AI-enhanced cloud-based software to offer real-time inventory and asset management, filling a crucial software integration gap for better penetration into the medical markets, including hospitals. We also amended our credit facility in the final week of June, increasing its size to approximately $1 billion and adding a $350 million accordion feature, giving us nearly $1.4 million of borrowing capacity over the next 5 years. This new pro rata bank facility gives us borrowing capacity to pursue our acquisition strategy while maintaining the debt leverage discipline we have practiced over the last decade. Now I'll share some additional performance metrics and some details on our operating segments. For the second quarter, Novanta had a 10% growth year-over-year in bookings and 20% growth sequentially and a book-to-bill ratio of 1.02, reflecting strengthening backlog and a strengthening outlook. We saw a continued strong pace of bookings in both our segments, demonstrating not only stabilization of demand, but also increased demand outlook for 2026 and the continued strong momentum of new product launches. In the second quarter, medical market sales represented 54% of total Novanta sales and advanced industrial markets represented 46% of total sales. New product sales grew by more than 50% year-over-year, and our vitality index climbed to 21% of total sales. We are seeing growth in new product sales across all businesses, but especially the Medical Solutions segment. Through the first half of the year, we launched over a dozen new products, mainly focused on high-growth end markets in advanced surgery and robotics and automation. Also in the quarter, as we mentioned, we saw excellent design win activity with the company-wide design wins growing over 150% year-over-year. The second quarter Automation Enabling Technologies segment revenue grew by 4% year-over-year, beating expectations and driven by continued strength in the Robotics and Automation business unit, which was up nearly 16% year-over-year. The book-to-bill in this segment was 1.05, and bookings were up 8% year-over-year and 17% sequentially, giving us improving customer visibility. Adjusted gross margin in this segment were approximately 49%, up 40 basis points year-over-year, driven by favorable mix, but partially offset by the increase in tariff costs. Both new product revenue and customer design wins doubled year-over-year on the back of both our innovation and stronger commercial execution by our teams. In addition, Vitality Index was in the high teens percent of sales, up significantly versus the prior year. Moving on to Medical Solutions. Revenue in this segment was roughly flat year-over-year. This segment saw a book-to-bill of 1 in the second quarter, and bookings were up 13% year-over-year, but up 26% sequentially on the back of record new product launches. New product sales in this segment grew by over 30% year-over-year, and the vitality index in this segment was over 25% of sales in the second quarter. Our Advanced Surgery business experienced 17% growth year-over-year, driven by both strong patient procedural growth rates in health care on a global basis and from the launch of our second-generation smoke evacuating insufflators, which has received overwhelming market acceptance and adoption. These growth dynamics are expected to continue for the remainder of the year and well into 2026. Conversely, our Precision Medicine business, which serves the life science and multiomics markets experienced a 13% decline in sales year-over-year. However, sequentially, the business grew 10% and is expected to continue to improve sequentially in subsequent quarters. Adjusted gross margins in this segment were approximately 44% in the quarter, flat sequentially and in line with the expectations for slightly higher tariff costs, which we expect to mitigate further in the third quarter. Finally, moving to guidance, let me give you an update on our tariff response plan. Speaking first, the impact of tariffs on our supply chain, our cost mitigations are largely on track, and we continue to work on efforts to accelerate our plans. With some of the recently announced trade deals at higher-than-expected permanent tariff rates, we are seeing approximately a $4 million net impact from tariffs year-to-date on our cost of sales. However, we continue to make strong progress with both tariff mitigation strategies and cost mitigation strategies to further reduce the impact in the second half. Next, to address the matter of impacts on tariffs between the United States and China, while tariffs have remained paused between the 2 countries, there is optimism of trade agreement being reached quickly. Our customers in China continue to be cautious with placing committed purchase orders on goods from our U.S. factories. As such, we are working with them on accelerating our plans to shift production to non-tariff regions and are exploring further short-term mitigation strategies to minimize their risk of ordering products from us. While Chinese customers ordering products from our U.S. factory has been muted, design win activities with our Chinese customers have accelerated, which we believe signals to us that our Chinese customers have confidence that we have the right tariff mitigation strategies to reduce their costs and risks and that they are excited about our new product innovation and what it can do for them in their markets. In addition, demand for our products manufactured in China, which is our in-China-for-China strategy, accelerated in the quarter, which drove our total China sales up 15% year-over-year in the quarter. And finally, due to the fluid and ever-changing nature of the global trade environment and the resulting implications on end market demand at the end of June, we launched our cost-reduction plans that we had previously announced, including changes that support the regional manufacturing strategy. Over the long run, we expect these actions to structurally improve our costs by simplifying our operating model, allowing further expansion of our gross margins while permanently minimizing the disruptions from tariffs on our products and for our customers. The total restructuring charges related to this program are expected to be in the $20 million to $25 million range, with the bulk of the savings run rating in the fourth quarter of 2025 and into 2026. Novanta is committed to deliver sequential revenue and profit growth driven by our innovation pipeline, robust customer demand in secular growth markets and operational discipline including our cost reduction efforts and the regional manufacturing strategy. Despite the rapid changes in tariffs and trade agreements, we believe we have navigated this well and have quickly adapted to the environment. After several years of investing heavily in R&D to deliver breakthrough innovations to our customers, the results of those efforts are materializing in our financials, in our design wins and in our new product revenue. And with a stabilizing demand environment as evident by our bookings growth, we believe we are well positioned to accelerate our organic growth initiatives further when the macroeconomic tailwinds improve. While trade dynamics could further disrupt our outlook, increased visibility from our customers is giving us confidence to reissue full year guidance, albeit with some caution. As such, we now expect full year 2025 GAAP revenue to be approximately $970 million to $985 million, which represents overall revenue growth of 2% to 4%. For adjusted gross margins, we expect to achieve approximately 46%. This outlook includes the cumulative impact of expected tariff costs and the associated temporary redundancy in costs from our regional manufacturing strategy. Excluding those extra costs, we would be on track to achieving our goal of 100 basis points of gross margin expansion this year. This resilient margin performance is thanks to the Novanta Growth System, the business system that is allowing us to maintain our financial commitments despite the cost headwinds. We expect R&D and SG&A expenses for the full year to be approximately 28% of sales or between $274 million and $278 million. This guidance excludes expected costs associated with the design and planning phase of a standard ERP system, which is scheduled for a phased deployment starting in 2026 and taking place over multiple years, further supporting our footprint consolidation and our regional manufacturing strategy. Besides improved scalability and resiliency benefits, this also supports our gross margin expansion plans and operating expense reduction plans. Depreciation expense should be approximately $16 million for the full year. Stock compensation expense should be approximately $37 million for the full year, which includes the change in incentive compensation plans, which we made for all our incentive-based employees, aligning them tightly with our strategy, driving strong employee engagement and aggressively driving shareholder value while also reducing near-term cash needs. For adjusted EBITDA and for the full year of 2025, we expect to be $225 million to $230 million or approximately a 23% EBITDA margin. This represents year-over-year growth of 7% to 10%. Interest expense is expected to be roughly $23 million for the full year of 2025, excluding any material changes in debt balances. We expect our non-GAAP tax rate to be around 22% for the full year. We are still analyzing the effects of the new corporate tax law changes and as such, have not incorporated these changes fully into our full year rate. Diluted weighted average shares outstanding will be between 36 million and 37 million shares. For the full year 2025, our adjusted diluted earnings per share, we now expect to be approximately $3.22 and $3.36, representing growth of 5% to 9%. Finally, we expect strong cash flow for the full year from both lower cash taxes in the second half as well as better inventory management and stronger profit. Moving to the third quarter of 2025. We expect GAAP revenue in the range of $244 million to $247 million, which represents a year-over-year change in reported revenue growth of flat to up 1% and sequential growth of 1% to 2%. At the segment level in the third quarter, we expect Automation Enabling Technologies segment to flat to low single-digit decline year-over-year, caused largely by lower exports from U.S. factories to Chinese customers, something we expect to better mitigate in the fourth quarter. We expect this segment to grow sequentially 1% to 2%. Our Medical Solutions segment is expected to demonstrate mid-single-digit growth year-over-year and up sequentially approximately 3% from continued strength in Advanced Surgery at growth rates comparable to those demonstrated in the second quarter and from a sequentially improving Precision Medicine business. Moving on to adjusted gross margin for the third quarter, we expect to be at nearly 46%. This outlook includes the cumulative impact of expected announced tariffs as well as some near-term redundancy costs from our regional manufacturing strategy, which we expect to overcome in the fourth quarter. We expect R&D and SG&A expenses in the third quarter to be approximately $68 million to $69 million. Similar to our full year guidance, we have excluded expected costs associated with the design and planning phase of our standard ERP system. Depreciation expense, which is approximately $4 million in the second quarter will be similar to the third quarter. Stock compensation expense was $7.5 million in the second quarter will be nearly $11 million in the third quarter. This increase in quarterly stock compensation expense is driven by both the retention and incentive equity awards associated with the Kion transaction as well as the in-quarter impact of the change of incentive compensation plans, which we discussed earlier. For adjusted EBITDA for the third quarter, we expect a range of $57 million to $60 million. Interest expense, which was $6 million in the second quarter, will be similar in the third quarter, and we expect our non-GAAP tax rate to be around 22%. For adjusted earnings per share, we expect a range of $0.78 to $0.85 for the third quarter. Finally, we expect third quarter cash flows to rebound versus the second quarter and return to a cash conversion rate closer to the historical averages we have demonstrated. This updated outlook considers our latest view of the end markets, the continued successes of our new product launches, foreign exchange rates based on the second quarter and the signed tariff agreements, trade agreements between the U.S. and its trading partners as of July month end. However, in this environment, the dynamics of both trade and foreign exchange as well as government-sponsored funding and regulatory disruptions is ever evolving and therefore, subject to change. But we continue to have confidence in our ability to navigate these dynamics and adapt quickly. And finally, with improvements to both our core business and long-term visibility to customer demand, along with a strong balance sheet and strong credit facility, we are well positioned to accelerate our acquisition pipeline with more meaningful and impactful acquisitions. Given our current acquisition pipeline, we feel confident in executing a transaction by year-end. In summary, we are confident in the fundamentals of our business, the long-term strategy and our business model remains intact. We are excited about our new customer wins and the success of new product launches. We continue to make strong progress in high-growth markets, particularly in medical markets and physical AI robotics markets. As a company, we remain focused on controlling what we can control and executing with excellence on our strategy and top priorities, no matter what the market environment brings. This concludes our prepared remarks. We'll now open the call up for questions.

Our first question will come from Lee Jagoda of CJS Securities.

I guess, Robert, just to start, can you break down your revenue guidance and you can use the midpoint, I guess, in terms of growth from Kion, the impact of FX and then the true organic growth underlying?

For the second half or for the full year?

Full year or second half, either one or both?

For the full year, on an organic basis, it will likely be down 1% to up 1%, somewhere in that range.

What is the implied impact or benefit from foreign exchange?

The same FX impact that we had in the second quarter. So we just carried that forward for the full year.

Got it.

So the delta is really the Kion acquisition. To be fair, it has done significantly better than expected.

Got it. And then I was hearing all the color around the new products over the next several years was really good and interesting earlier. Given you kind of have pretty good visibility about your product road map, what do you think are the biggest drivers of organic growth in 2026 in terms of the new products independent of whatever the market is going to do?

Yes, this is Matthijs. We're continuing to ramp up our advanced surgery products, with this year marking our first year of those ramps and expecting further expansion. Additionally, in the physical AI sector, which includes AI-enabled robotics for warehouse automation, we've secured a $50 million contract and are witnessing rapid implementation of robotics in advanced warehouse applications. These robots require touch sensitivity and quick, safe movement, and we possess unique capabilities to enhance that functionality. Moreover, while humanoid applications may remain small, we anticipate that overall industrial physical AI applications will see growth, potentially doubling in 2026 compared to 2025, and then doubling again from a small base, indicating growth in that sector. We are also observing strong design wins that will begin to ramp up, projecting a 150% year-over-year increase at the company level. While not all will fully ramp in 2026, they will start to make progress, offering us visibility across a variety of applications. For example, additive manufacturing in aerospace and medical sectors is gaining traction, as the current tariffs and trade environment is prompting companies to produce locally, with additive manufacturing being an effective solution. We've secured significant business in this area as well as in advanced material processing applications that support on-device AI initiatives in advanced packaging related to AI and similar markets. These are a few of the growth prospects we are excited about, demonstrating our commitment to thriving in secular growth markets regardless of environmental challenges. With a focus on innovation and customer relations, we remain optimistic about the developments in this space.

And then within life sciences...

One thing I'd add there is that we're excited about investments in advanced packaging related to advanced AI and other related markets. We see growth in these areas regardless of the environmental conditions. This demonstrates our commitment to focusing on secular growth markets. Additionally, we are very encouraged by the innovation and customer intimacy developments.

Yes, go ahead.

The only thing I was going to add is that the Advanced Surgery business should continue to demonstrate the same level of growth, which is kind of the mid-teens type growth as we get into next year. Our Robotics and Automation business should continue to participate as a consequence of new design wins and new product introductions, somewhere in that 10% type of range. And then if you just factor in that you're not going to see the same level of declines in our Industrial or Precision Manufacturing business nor the Precision Medicine business, that would give you a pretty good indicator of what 2026 is going to look like.

Well, and that's sort of where I was going to go next. So in Industrial and Precision Medicine, it sounds like you're seeing certainly some signs of improvement in the industrial and maybe at a minimum bouncing along the bottom in life sciences. So I guess, have we seen the low point for the year in your mind in those 2 areas? And sitting here today, are we looking at sort of a flattish 2026 for those end markets? Or could they still decline further?

Well, based on what we see today, and again, you never know with, of course, the trade changes. But based on what we see today, based on the bookings and the customer outlook, which is actually improving, right? Customer inventories on the industrial side have been depleted. And so we see 2026 backlog actually building on the industrial side, and we see the business sequentially improving in the second half of the year. So based on that, yes, we see that business has reached bottom and then sequentially improving from here. The Precision Medicine also we commented that, that's more of a technology shift in addition to market dynamics. The market dynamics, we don't necessarily see improving in the near term, but we do see the technology shift based on the machine vision as well as the RFID transitions that we're making. We see that having a sequential improving effect on the business. And therefore, we see that business sequentially improving as well. So yes. And then the outlook for life science is a little bit unclear, but what we do is we just focus on what we can control, which is those new technologies as well as we're aggressively managing profit flow-through as well as capital allocation, of course, to these areas that have really strong tailwinds like physical AI, advanced surgery.

The next question comes from Brian Drab of William Blair.

First, Robert, you touched on China and tariffs. Did you say specifically status? Did you talk about in the same context about the $35 million that was held up? And is that still $35 million at risk for the year?

Yes, the $35 million is included in our current guidance, but we have not yet assumed we will recover that amount. I want to emphasize this caution in our guidance. We are not currently seeing the order activity from our customers in the second quarter, and this trend has continued into August. This is primarily due to the uncertainty surrounding the tariffs. When ordering products from a U.S. factory that has a 90-day lead time, there is a risk with noncancelable purchase orders, as they might have to import at an uncertain cost due to unknown tariff expenses. On a positive note, we are experiencing growth in China. Our strategy focused on China, which constitutes 50% of our overall sales there, is expanding, and we reported a 15% increase in total China sales year-over-year. Despite the challenges, we are seeing significant growth. Furthermore, the design win activities with our Chinese customers are picking up pace, indicating that they are interested in incorporating our technology into new products, which suggests they do not view the current situation as permanent. Is it possible to turn this around by the fourth quarter? Yes, it is possible, although not by the third quarter. We could potentially start to recover some of that revenue in the fourth quarter, but as of now, we haven't included that in our plans until we gain more clarity on the execution.

And of course, it's driven, Brian, by the transfer of manufacturing, right? So our customers, we've shared those plans. They're confident in our plans. That's why the design wins are continuing. And of course, the actual transfers are starting to happen in the fourth quarter, which is really the mitigation, right? So then it really depends how quickly can you rectify and ramp from there. But structurally, we're addressing it. It's really a timing issue that we're working through.

Understood. Are those design wins in China, medical, industrial, robotic surgery, did you say?

Mostly industrial.

Mostly industrial and robotics. Our Robotics and Automation business, of course, Matthijs went into some details around that. There's a lot of new products launched around that, but we're also seeing nice design win activities in our Precision Manufacturing business.

Okay. Can you say if any of those humanoids?

We mentioned 10 humanoids from vendors or customers. We were very clear that there are U.S. and European exposures. The majority of our humanoid exposure today is in the U.S. and European markets. We would be hesitant to say there is anything in China at this point.

Yes, there is some interest, but it is limited. We are not relying heavily on that, but there are other markets for precision robotics, including surgical and areas related to warehouse automation, that are gaining traction and where we believe we have a strong offering.

Okay. And then just one more for now, I guess. Can you talk a little bit more about maybe the specific use case within the warehouse for the warehouse robotics win? And what type of technology are you winning with? Like is it force torque or servo drives, haptic? And then I've got one more piece to this question. Could this be much bigger than $50 million down the road?

Yes, thank you, Brian. Let me break that down. First, vision alone isn’t sufficient in advanced warehouse automation markets, where goods are processed faster than humans. It's essential to replicate human touch, as demonstrated by a leading player, highlighting its importance. Fast and safe reactions to sensory inputs and translating that into motion is complex, especially in a small form factor at the action site. Novanta has unique capabilities to accomplish this precisely and reliably, meeting the high demands of applications where dropping a package is extremely rare, requiring exceptional accuracy. This capability instills confidence in warehouse automation providers to replace humans. Additionally, significant capital is being invested, which is publicly available information. We see a clear use case that has been validated in warehouses, and while it will involve a multi-year deployment cycle, we only mention contract wins with confirmed agreements, such as the $50 million deal. We believe that if we consider all physical AI applications, the addressable market for us could reach around $1 billion by 2030, and we aim to capture a significant share of that. We are aggressively allocating resources to ramp up and sustain our new product innovations, which we are confident are industry-leading. This includes force torque sensing, servo drives, and encoders, all within a subsystem package tailored for various OEM applications, whether in warehouse automation, humanoids, or other related uses. It's important to note that robots do not have to operate on two feet; many applications involve robots on wheels or stationary units performing intelligent tasks. I hope that clarifies your question.

Yes, that was really interesting. And congrats on the warehouse win and all the other wins you announced this quarter.

The next question comes from Rob Mason of Baird.

Maybe just a follow-up on your last response, Matthijs. When you were discussing the complete package of your offering in this market, including force torque, servo drives, and encoders, was that applicable to this specific warehouse automation contract? Or was it solely focused on force torque since you primarily mentioned sensing?

Well, it's about sensing in their reaction. It includes both the servo drives and the sensing capabilities. We're discussing one particular player, but we have secured several design wins in warehouse automation that are smaller, utilizing a full range of our different capabilities. The extent to which each capability is used varies by the player. However, it's generally true that both in warehouse automation, humanoids, and surgical robotics, these capabilities are increasingly important. For instance, haptic feedback in surgical robotics is crucial. This same capability also provides the robot in the warehouse a sense of touch, as well as for humanoids. Additionally, low latency, which ensures quick and safe responses, allows humans to work alongside these robots without issues. Implementing this safely within our servo drives is challenging, yet we achieve it with a compact design that is highly precise and boasts a great power density. This means our small form factor is indeed very powerful. All these elements combined make us uniquely qualified for these applications. In summary, both capabilities are integral to these applications.

I see. I see. And just as you've talked about kind of the ramp in these products in '26 and '27, are you needing to add additional capacity? Do you have current capacity to serve this?

Yes, we do. I'm glad you asked this question because it's a perfect example of how the Novanta Growth System can effectively increase capacity. We recently completed a kaizen with over 20 people, significantly reducing lead times by a factor of 3 and boosting capacity by 4 to 5 times without major enhancements. Looking ahead, we anticipate this ramp to grow even further. Eventually, we will need to automate and integrate more automation into our lines to manage these high volumes. So yes, we're leveraging the Novanta Growth System to achieve this efficiently and reliably.

I see. And maybe just last question. One of the end markets you touched on, you said was mixed was around the semiconductor electronics area. I'm just curious, I mean, we have seen really over the past year, I guess, some pushes to the right in that industry. How does that factor into your second half guide around new products, whether that gets into the lithography space you're talking about? I'm just curious if you've had to shuffle some of the plans again around that?

Yes. Any risks linked to those applications have been incorporated into our guidance for the second half, along with the earlier mentioned situation in China, where we do not expect that revenue to rebound in our forecasts, although it seems increasingly possible, especially as we approach Q4. We are shipping units for those applications in the fourth quarter, though not at the volumes we initially hoped for. However, we remain confident because we are still a sole-source supplier for those applications. We have increased our content per unit compared to previous periods and maintain some backward compatibility with our technology. We believe we have the right technology and applications positioned for growth as a sole-source provider. We are just waiting for the market to work through certain dynamics that will enable those shipments to increase to the volumes we aim for and have previously communicated.

This concludes our question-and-answer session. I would like to turn the conference back over to Mr. Matthijs Glastra for any closing remarks.

Thank you, operator, and thank you, everyone, for your questions. In closing, as always, I would like to thank our customers, our shareholders and especially our dedicated employees for their ongoing support. We appreciate your interest in the company, your participation in today's call. I look forward to joining all of you soon at our third quarter 2025 earnings call. Thank you very much. This call is now adjourned.

The conference has now concluded. Thank you for attending today's presentation, and you may now disconnect.